Someone mentioned earlier that they'd had it briefly examined by someone in a relevant field - I believe it was a biosystems engineer or other med tech role. They felt it was replicable too. I've also discussed GMV at work (hospital) with a couple of departments and replicability is apparently not an issue. I was told that most companies in this arena should ideally be heading roughly towards the same point and that this is an indication that they're on the right track. I did not discuss actual detail - but will do so when I return to work. I will update on this thread at that time.
T.
GMV Price at posting:
16.0¢ Sentiment: Buy Disclosure: Held
